Menu Search
Equities

Joinn Laboratories China Co Ltd

6127:HKG.HS

Joinn Laboratories China Co Ltd

Actions
  • Price (HKD)30.50
  • Today's Change-0.75 / -2.40%
  • Shares traded89.39k
  • 1 Year change-58.54%
  • Beta--
Data delayed at least 15 minutes, as of Oct 06 2022 09:08 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Joinn Laboratories China Co Ltd is a China-based company primarily engaged in the pharmacology and toxicology research of new drugs. Non-clinical research services include drug safety evaluation, pharmacokinetic research as well as pharmacological and pharmacodynamic research. Clinical trials and related services include clinical contract research organization services, phase I clinical research collaboration unit (CRU), and bioanalysis services. Experimental model business mainly includes rodents and non-human primates. The Company conducts its businesses both in the domestic market and overseas markets.

  • Revenue in CNY (TTM)1.76bn
  • Net income in CNY774.84m
  • Incorporated1998
  • Employees2.14k
  • Location
    Joinn Laboratories China Co LtdA5 Rongjing East StreetEconomic-Technological Development AreaBEIJING 100176ChinaCHN
  • Phone+86 1 067869582
  • Fax+86 1 067869966
  • Websitehttp://www.joinn-lab.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		603127:SHH since
announced		Transaction
value
Guangxi Weimei Bio-Tech Co LtdDeal completed29 Apr 202229 Apr 2022Deal completed-38.32%147.13m
Yunnan Yinmore Bio-Tech Co LtdDeal completed29 Apr 202229 Apr 2022Deal completed-38.32%125.23m
Data delayed at least 15 minutes, as of Sep 30 2022 08:00 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.